Analysis of short‐term behavioral effects of dietary cholesterol supplementation in Smith–Lemli–Opitz syndrome
- 23 December 2009
- journal article
- research article
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 152A (1), 91-95
- https://doi.org/10.1002/ajmg.a.33148
Abstract
Smith–Lemli–Opitz syndrome (SLOS) is an inborn error of cholesterol synthesis due to mutations of 7‐dehydrocholesterol reductase (DHCR7). DHCR7 catalyzes the reduction of 7‐dehydrocholesterol (7DHC) to yield cholesterol in the final step of cholesterol biosynthesis. Phenotypically patients with SLOS have multiple malformations, cognitive deficits, and behavioral difficulties. Impaired DHCR7 activity results in the accumulation of 7DHC and frequently decreased cholesterol in blood and tissues. Dietary cholesterol supplementation has become standard therapy for SLOS, and anecdotal reports suggest rapid, marked clinical improvement of behavior problems. Although reported in the literature, beneficial behavioral effects of dietary cholesterol supplementation have not been formally documented through a randomized clinical trial. To address this we initiated a double‐masked, placebo‐controlled, cross‐over trial to test the hypothesis that dietary cholesterol supplementation has rapid beneficial effects on behavior. Our primary outcome measure was the hyperactivity subscale of the Aberrant Behavior Checklist (ABC). Hyperactivity is a symptom that has been reported to respond rapidly to dietary cholesterol supplementation. Secondary outcome measures included the total ABC score and other ABC subscale scores. Ten subjects completed this study. Although the trial was done under conditions similar to those reported to induce marked behavioral changes in SLOS patients, we observed no differences between treatment and placebo phases. The results of this study call into question anecdotal reports supporting rapid behavioral benefits previously reported for dietary cholesterol supplementation in SLOS and underscore the need for a larger placebo‐controlled trial.Keywords
This publication has 14 references indexed in Scilit:
- Central nervous system: cholesterol turnover, brain development and neurodegenerationBiological Chemistry, 2009
- Smith–Lemli–Opitz syndrome: pathogenesis, diagnosis and managementEuropean Journal of Human Genetics, 2008
- The near universal presence of autism spectrum disorders in children with Smith–Lemli–Opitz syndromeAmerican Journal of Medical Genetics Part A, 2006
- Cholesterol supplementation does not improve developmental progress in Smith-Lemli-Opitz syndromeThe Journal of Pediatrics, 2004
- The implications of 7-dehydrosterol-7-reductase deficiency (Smith–Lemli–Opitz syndrome) to neurosteroid productionSteroids, 2004
- SMITH-LEMLI-OPITZ SYNDROMEJournal of the American Academy of Child & Adolescent Psychiatry, 2001
- The Smith-Lemli-Opitz syndromeJournal of Medical Genetics, 2000
- Smith-Lemli-Opitz Syndrome Is Caused by Mutations in the 7-Dehydrocholesterol Reductase GeneAmerican Journal of Human Genetics, 1998
- Mutations in the Δ7-sterol reductase gene in patients with the Smith–Lemli–Opitz syndromeProceedings of the National Academy of Sciences of the United States of America, 1998
- Mutations in the Human Sterol Δ7-Reductase Gene at 11q12-13 Cause Smith-Lemli-Opitz SyndromeAmerican Journal of Human Genetics, 1998